PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
[18 F]Fluoro-3,4-dihydroxyphenyl-L-alanine (FDOPA) was one of the first successful tracers for molecular imaging by positron emission tomography (PET), and has proven immensely valuable for studies of Parkinson’s disease. Following intravenous FDOPA injection, the decarboxylated metabolite [18 F] fluorodopamine is formed and trapped within terminals of the nigrostriatal dopamine neurons; reduction in the simple ratio between striatum and cerebellum is indicative of nigrostriatal degeneration. However, the kinetic analysis of dynamic FDOPA-PET recordings is formidably complex due to the entry into brain of the plasma metabolite O-methyl-FDOPA and due to the eventual washout of decarboxylated metabolites. Linear graphical analysis relative to a reference tissue input function is popular and convenient for routine clinical studies in which serial arterial blood samples are unavailable. This simplified approach has facilitated longitudinal studies in large patient cohorts. Linear graphical analysis relative to the metabolite-corrected arterial FDOPA input yields a more physiological index of FDOPA utilization, the net blood-brain clearance. Using a constrained compartmental model, FDOPA-PET recordings can be used to calculate the relative activity of the enzyme DOPA decarboxylase in living brain. We have extended this approach so as to obtain an index of steady-state trapping of [ 18 F]fluorodopamine in synaptic vesicles. Although simple methods of image analysis are sufficient for the purposes of routine clinical studies, the more complex approaches have revealed hidden aspects of brain dopamine in personality, healthy aging, and in the pathophysiologies of Parkinson’s disease and schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652
Elevated dopa decarboxylase activity in living brain of patients with psychosis
Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342
Self-citationWorking Memory Capacity Predicts Dopamine Synthesis Capacity in the Human Striatum
Cools, R., Gibbs, S. E., Miyakawa, A., Jagust, W., & D'Esposito, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4475-07.2008 · Cited by 302
Heinz, A., Siessmeier, T., Wrase, J., Buchholz, H. G., Gründer, G., Kumakura, Y., Cumming, P., Schreckenberger, M., Smolka, M. N., Rösch, F., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1515 · Cited by 285
Self-citationDopamine in amygdala gates limbic processing of aversive stimuli in humans
Kienast, T., Hariri, A. R., Schlagenhauf, F., Wrase, J., Sterzer, P., Buchholz, H. G., Smolka, M. N., Gründer, G., Cumming, P., Kumakura, Y., et al. (2008) · Nature Neuroscience · doi:10.1038/nn.2222 · Cited by 177
Self-citationHigh Levels of Dopamine Activity in the Basal Ganglia of Cigarette Smokers
Salokangas, R. K. R., Vilkman, H., Ilonen, T., Taiminen, T., Bergman, J., Haaparanta, M., Solin, O., Alanen, A., Syvã«¡hti, E., & Hietala, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.632 · Cited by 164
Personality traits and brain dopaminergic function in Parkinson's disease
Kaasinen, V., Nurmi, E., Bergman, J., Eskola, O., Solin, O., Sonninen, P., & Rinne, J. O. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231313198 · Cited by 148
Yatham, L. N., Liddle, P. F., Shiah, I.-S., Lam, R. W., Ngan, E., Scarrow, G., Imperial, M., Stoessl, J., Sossi, V., & Ruth, T. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.768 · Cited by 122
Research works printed but not linked: 75
- 10.1016/S0006-2952(97)00031-2 · DOI
- 10.1016/0024-3205(86)90403-0 · DOI
- 10.1016/S0022-510X(99)00127-6 · DOI · Paper page
- 10.1002/(SICI)1098-2396(199911)34:2<111::AID-SYN4>3.0.CO;2-0 · doi:10.1002/(sici)1098-2396(199911)34:2<111::aid-syn4>3.0.co;2-0
- 10.1016/j.neurobiolaging.2004.07.014 · DOI
- 10.1002/mds.20855 · DOI
- 10.1016/0006-2952(95)00216-M · doi:10.1016/0006-2952(95)00216-m
- 10.1111/j.1471-4159.1987.tb04135.x · DOI · Paper page
- 10.1002/(SICI)1098-2396(199805)29:1<37::AID-SYN4>3.0.CO;2-C · DOI · Paper page
- 10.1016/0006-2952(88)90725-3 · DOI
- 10.1046/j.1471-4159.1995.65031381.x · DOI · Paper page
- 10.1038/jcbfm.1993.85 · DOI · Paper page
- 10.1002/syn.1077 · doi:10.1002/syn.1077
- 10.3727/000000002783985314 · DOI
- 10.1002/(SICI)1098-2396(19990915)33:4<247::AID-SYN1>3.0.CO;2-6 · doi:10.1002/(sici)1098-2396(19990915)33:4<247::aid-syn1>3.0.co;2-6
- 10.1016/S0165-0270(97)00094-0 · DOI
- 10.1016/S0165-0270(97)00147-7 · DOI
- 10.1097/00004647-199903000-00006 · doi:10.1097/00004647-199903000-00006
- 10.1016/j.neuroimage.2005.09.044 · DOI
- 10.1016/S0024-3205(97)00300-7 · doi:10.1016/s0024-3205(97)00300-7
- 10.1111/j.1471-4159.1987.tb05629.x · DOI
- 10.1038/305137a0 · DOI · Paper page
- 10.1111/1467-9450.00347 · DOI
- 10.1016/0165-0173(82)90018-2 · DOI · Paper page
- 10.1073/pnas.88.7.2721 · DOI · Paper page
- 10.1038/sj.npp.1300103 · DOI
- 10.1007/BF01250373 · DOI
- 10.1016/S0920-9964(98)00113-3 · DOI · Paper page
- 10.1001/archneur.62.3.378 · DOI · Paper page
- Holden JE, 1997, J Nucl Med, 38, 1568
- 10.1038/jcbfm.1993.8 · DOI · Paper page
- 10.1038/jcbfm.1991.155 · doi:10.1038/jcbfm.1991.155
- 10.1016/j.biopsych.2007.04.017 · DOI
- Ishiwata K., 2007, J Nucl Med, 48, 81
- 10.1023/A:1022478417383 · DOI
- 10.1016/S0304-3940(02)00929-1 · DOI
- 10.1093/brain/124.6.1125 · DOI · Paper page
- Kish SJ, 1995, nn Neurol, 38, 260
- 10.1111/j.1460-9568.2007.05580.x · DOI
- 10.1523/JNEUROSCI.0805-07.2007 · DOI · Paper page
- 10.1038/sj.jcbfm.9600202 · DOI
- Kumakura Y., 2008, Neurobiol Aging
- 10.1038/sj.jcbfm.9600079 · DOI
- 10.1016/S0006-3223(02)01369-0 · DOI · Paper page
- 10.1176/appi.ajp.160.5.904 · DOI · Paper page
- 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4 · DOI · Paper page
- 10.1002/(SICI)1098-2396(199812)30:4<351::AID-SYN2>3.0.CO;2-2 · doi:10.1002/(sici)1098-2396(199812)30:4<351::aid-syn2>3.0.co;2-2
- 10.1016/S0006-3223(99)00109-2 · DOI · Paper page
- 10.1002/syn.20016 · DOI
- 10.1002/ana.410260407 · DOI · Paper page
- 10.1001/archpsyc.61.2.134 · DOI · Paper page
- 10.1176/jnp.7.2.176 · DOI · Paper page
- 10.1136/jnnp.59.6.597 · DOI · Paper page
- 10.1002/mds.1139 · DOI · Paper page
- 10.2741/1104 · DOI
- 10.1002/ana.410340306 · DOI · Paper page
- 10.1038/jcbfm.1985.87 · DOI · Paper page
- 10.1038/jcbfm.1983.1 · DOI · Paper page
- 10.1002/ana.410060502 · DOI · Paper page
- 10.1097/00004647-200107000-00003 · DOI
- 10.1093/brain/122.9.1637 · DOI · Paper page
- 10.1001/archneur.57.4.470 · DOI · Paper page
- 10.1002/1098-2396(200008)37:2<81::AID-SYN1>3.0.CO;2-# · DOI · Paper page
- 10.1111/j.1460-9568.2006.04903.x · DOI · Paper page
- 10.1002/ana.410340304 · DOI · Paper page
- 10.1097/01.WCB.0000126563.85360.75 · DOI · Paper page
- 10.1097/00004647-200104000-00015 · DOI · Paper page
- 10.1097/00004647-199910000-00011 · DOI
- 10.1002/syn.20157 · DOI
- 10.1002/hbm.20325 · DOI · Paper page
- 10.1016/j.neuroimage.2007.12.045 · DOI
- 10.1016/j.neuroimage.2005.11.014 · DOI
- 10.1002/ana.10609 · DOI · Paper page
- 10.1046/j.1471-4159.2000.741147.x · DOI
- 10.1002/mds.1168 · DOI
Cited by
Applications of Fluorine in Medicinal Chemistry
Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,618
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“…measured using PET thus provides an index of presynaptic dopamine synthesis capacity and the availability of dopamine for release from presynaptic terminals (see review by Kumakura and Cumming, 2009), and shows good test–retest reliability in dopaminergic regions (Egerton et al., 2010a).”
MethodDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Metadata
- Authors
- Kumakura, Y., & Cumming, P.
- Venue
- The Neuroscientist
- Publisher
- SAGE Publications
- Published
- 2009-09-29
- Volume
- 15
- Issue
- 6
- Pages
- 635-650
- ISSN
- 1073-8584 (ISSN-L)
- 1089-4098
- OpenAlex
- W2073328025
- Cited by
- 134
- References
- 8
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches. https://app.cochat.ai/papers/10.1177/1073858409338217
- The paper
- Kumakura, Y., & Cumming, P. (2009). PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches. The Neuroscientist. https://doi.org/10.1177/1073858409338217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.